ESAFacts.org

Information for Physicians and Patients

Information from the Journal of the American Medical Association

A new meta-analysis was published 02-27-2008.

You can read the summary at http://jama.ama-assn.org/cgi/content/abstract/299/8/914. The author's conclusion, as stated in the free abstract of the longer paper is quoted here:

Conclusions: "Erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of VTE and mortality. Our findings, in conjunction with basic science studies on erythropoietin and erythropoietin receptors in solid cancers, raise concern about the safety of ESA administration to patients with cancer."